Company Profile

XenoPort, Inc.

Company Overview

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate, gabapentin enacarbil, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. New drug applications have been filed for gabapentin enacarbil in Japan (by Astellas) for the potential treatment of restless legs syndrome and in the United States (by GSK) for the potential treatment of moderate-to-severe primary restless legs syndrome.

XenoPort’s product candidates are also being studied for the potential treatment of gastroesophageal reflux disease, neuropathic pain, spasticity and Parkinson’s disease.

For more information, please visit

Positions Available
This company currently has no jobs posted.

Click here to search for jobs.